Kezar Life Sciences
136 hedge funds and large institutions have $188M invested in Kezar Life Sciences in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 51 increasing their positions, 39 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
136
Holders Change
+13
Holders Change %
+10.57%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
30
Increased
51
Reduced
39
Closed
17
Calls
$2.91M
Puts
$2.36M
Net Calls
+$547K
Net Calls Change
-$918K
Top Buyers
| 1 |
SCM
Suvretta Capital Management
New York
|
$21.6M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
$10M |
| 3 |
Citadel Advisors
Miami,
Florida
|
$3.02M |
| 4 |
O
OrbiMed
New York
|
$17.1M |
| 5 |
Barclays
London,
United Kingdom
|
$2.59M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
$0 |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
$31.3K |
| 3 |
CA
CHI Advisors
New York
|
$2.16M |
| 4 |
TLP
Tri Locum Partners
New York
|
$0 |
| 5 |
State Street
Boston,
Massachusetts
|
$10.1M |
